ATE403425T1 - Feste formulierungen enthaltend eine indolinon verbindung - Google Patents

Feste formulierungen enthaltend eine indolinon verbindung

Info

Publication number
ATE403425T1
ATE403425T1 AT03772489T AT03772489T ATE403425T1 AT E403425 T1 ATE403425 T1 AT E403425T1 AT 03772489 T AT03772489 T AT 03772489T AT 03772489 T AT03772489 T AT 03772489T AT E403425 T1 ATE403425 T1 AT E403425T1
Authority
AT
Austria
Prior art keywords
formulations containing
solid formulations
indolinone compound
indolinone
compound
Prior art date
Application number
AT03772489T
Other languages
English (en)
Inventor
Paolo Gatti
Original Assignee
Pfizer Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE403425(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Italia Srl filed Critical Pfizer Italia Srl
Application granted granted Critical
Publication of ATE403425T1 publication Critical patent/ATE403425T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03772489T 2002-09-10 2003-09-10 Feste formulierungen enthaltend eine indolinon verbindung ATE403425T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42113302P 2002-09-10 2002-09-10

Publications (1)

Publication Number Publication Date
ATE403425T1 true ATE403425T1 (de) 2008-08-15

Family

ID=31994326

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03772489T ATE403425T1 (de) 2002-09-10 2003-09-10 Feste formulierungen enthaltend eine indolinon verbindung

Country Status (32)

Country Link
US (1) US20040229930A1 (de)
EP (1) EP1536783B2 (de)
JP (1) JP2006503032A (de)
KR (1) KR20050059170A (de)
CN (1) CN1688304A (de)
AR (1) AR041193A1 (de)
AT (1) ATE403425T1 (de)
AU (1) AU2003280108B2 (de)
BR (1) BR0314182A (de)
CA (1) CA2498415C (de)
DE (1) DE60322720D1 (de)
DK (1) DK1536783T3 (de)
DO (1) DOP2003000708A (de)
ES (1) ES2309363T5 (de)
GT (1) GT200300193A (de)
HN (1) HN2003000272A (de)
MX (1) MXPA05002690A (de)
MY (1) MY136767A (de)
NL (1) NL1024261C (de)
NO (1) NO20051670L (de)
NZ (1) NZ538636A (de)
PA (1) PA8581801A1 (de)
PE (1) PE20040989A1 (de)
PL (1) PL375978A1 (de)
PT (1) PT1536783E (de)
PY (1) PY0323128A (de)
RU (1) RU2005110663A (de)
SI (1) SI1536783T1 (de)
TW (1) TW200418836A (de)
UY (1) UY27969A1 (de)
WO (1) WO2004024127A2 (de)
ZA (1) ZA200501897B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ546001A (en) * 2003-10-02 2009-09-25 Pharmacia & Upjohn Co Llc Salts and polymorphs of a pyrrole-substituted indolinone compound
KR20080040007A (ko) * 2005-09-20 2008-05-07 화이자 프로덕츠 인크. 티로신 키나제 억제제를 이용한 치료의 투여형 및 방법
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
US20080045548A1 (en) * 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP2220071A2 (de) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib-hemi-l-malat, polymorphe und herstellung davon, polymorphe von racemischem sunitinib-malat, sunitinib base und äpfelsäure enthaltende zusammensetzungen und herstellung davon
CA2713112A1 (en) * 2008-02-13 2009-08-20 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2113248A1 (de) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-[2-(Diethylamino)ethyl]-5-[(5-Fluor-1,2-dihydro-2-oxo-3H-Indol-3-yliden)methyl]-2-,4Dimethyl-1H-Pyrrol-3-Carboxamid
EP2090306A1 (de) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmazeutische Zusammensetzungen mit N-[2-(Diethylamino)ethyl]-5-[5-fluor-1,2-dihydro-2-oxo-3H-indol-3-yliden)methyl]-2,4-dimethyl-1H-pyrrol-3-carboxamid
EP2138167A1 (de) * 2008-06-24 2009-12-30 ratiopharm GmbH Pharmazeutische Zusammensetzung mit N-[2-(Diethylamino)ethyl]-5-[(5-Fluor-1,2-dihydro-2-oxo-3H-Indol-3-yliden)methyl]-2,4-Dimethyl-1H-Pyrrol-3-Carboxamid
CA2731605A1 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
WO2010039798A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN103301116A (zh) * 2012-03-16 2013-09-18 大鹏药品工业株式会社 口服医药组合物
RU2737765C2 (ru) 2012-05-04 2020-12-02 Пфайзер Инк. Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
WO2015063647A1 (en) 2013-11-01 2015-05-07 Pfizer Inc. Vectors for expression of prostate-associated antigens
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
EP3539536A1 (de) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia Pharmazeutische zusammensetzung von sunitinib oder salz davon in seiner polymorphen form i
WO2020146441A1 (en) * 2019-01-09 2020-07-16 Celgene Corporation Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
US20230355581A1 (en) * 2020-07-02 2023-11-09 The Board of Regents of the Unversity of Texas System Methods of treatment for melanoma
DK4178548T3 (da) 2020-07-07 2024-08-19 Celgene Corp Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
WO2001037820A2 (en) * 1999-11-24 2001-05-31 Sugen, Inc. Ionizable indolinone derivatives and their use as ptk ligands
DE19956598A1 (de) * 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
JP3663382B2 (ja) * 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換２−インドリノン蛋白質キナーゼ阻害剤
CN100364991C (zh) * 2001-08-15 2008-01-30 法玛西雅厄普约翰美国公司 2,4-二甲基-1h-吡咯-3-甲酰胺衍生物的苹果酸盐的晶体、其制备方法和其组合物
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds

Also Published As

Publication number Publication date
AR041193A1 (es) 2005-05-04
MY136767A (en) 2008-11-28
MXPA05002690A (es) 2005-05-05
RU2005110663A (ru) 2005-09-10
NL1024261C (nl) 2010-04-06
US20040229930A1 (en) 2004-11-18
WO2004024127A2 (en) 2004-03-25
ES2309363T5 (es) 2011-12-07
UY27969A1 (es) 2004-04-30
NL1024261A1 (nl) 2004-03-11
ZA200501897B (en) 2005-09-07
AU2003280108A1 (en) 2004-04-30
PL375978A1 (pl) 2005-12-12
AU2003280108B2 (en) 2007-04-05
TW200418836A (en) 2004-10-01
NZ538636A (en) 2006-04-28
EP1536783B1 (de) 2008-08-06
PE20040989A1 (es) 2004-12-28
CA2498415A1 (en) 2004-03-25
HN2003000272A (es) 2008-07-29
PA8581801A1 (es) 2005-02-04
JP2006503032A (ja) 2006-01-26
EP1536783B2 (de) 2011-08-24
CN1688304A (zh) 2005-10-26
CA2498415C (en) 2007-05-29
SI1536783T1 (sl) 2008-12-31
PY0323128A (es) 2012-12-03
KR20050059170A (ko) 2005-06-17
WO2004024127A3 (en) 2004-06-03
PT1536783E (pt) 2008-10-10
NO20051670L (no) 2005-04-04
GT200300193A (es) 2004-04-29
DK1536783T3 (da) 2008-10-13
BR0314182A (pt) 2005-08-09
DOP2003000708A (es) 2004-03-31
EP1536783A2 (de) 2005-06-08
DE60322720D1 (de) 2008-09-18
ES2309363T3 (es) 2008-12-16

Similar Documents

Publication Publication Date Title
ATE403425T1 (de) Feste formulierungen enthaltend eine indolinon verbindung
HUS2200020I1 (hu) Aktív vegyületeket tartalmazó fungicid kombinációk
PT1501534E (pt) Formulacoes farmaceuticas
NO20033556L (no) Farmasöytiske formuleringer
EP1552833A4 (de) Stabile feste zubereitungen
FI20011478A0 (fi) Farmaseuttinen koostumus
DE60325255D1 (de) Duftzusammensetzung
EP1653935A4 (de) Entzündungshemmende formulierungen
NO20043418L (no) Stabiliserte adenovirusformuleringer
ATE368042T1 (de) Cephemverbindungen
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
DE60334074D1 (de) Chemische verbindung
EP1559433A4 (de) Stabilisierte zusammensetzung
DE60312049D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
IS7414A (is) Oxó-azabísýklísk efnasambönd
EE200300589A (et) Ravimkoostised
IS8309A (is) Lyfjablöndur
DK1539089T3 (da) Reducerede aerosol-genererende formuleringer
FI20022128A7 (fi) Farmaseuttinen koostumus
EP1692279A4 (de) Konservierungsstoffhaltige virusformulierungen
IS7715A (is) Nýjar lyfjasamsetningar úr módafíníl
IS7500A (is) thurrdufts samsetningar
EP1490040A4 (de) Entzündungshemmende formulierungen
NO20034952D0 (no) Farmasöytiske forbindelser
NO20033073D0 (no) Farmasöytisk sammensetning inneholdende citalopram

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1536783

Country of ref document: EP

REN Ceased due to non-payment of the annual fee